Zafgen, Inc. (ZFGN) News
Filter ZFGN News Items
ZFGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ZFGN News From Around the Web
Below are the latest news stories about Zafgen Inc that investors may wish to consider to help them evaluate ZFGN as an investment opportunity.
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar TherapeuticsChondrial Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the completion of its reverse merger with Zafgen, Inc. (ZFGN). The combined, publicly traded clinical-stage biotechnology company will operate under the name Larimar Therapeutics, Inc. and its shares will commence trading on the Nasdaq Global Market on May 29, 2020, under the ticker symbol “LRMR.” |
Zafgen Reports Fourth Quarter and Full Year 2019 Financial ResultsZafgen and Chondrial Therapeutics previously announced a definitive merger agreement Merger creates clinical-stage company focused on the development of novel protein. |
5 Deep-Value Stocks for 2020A look at some stocks Benjamin Graham might have liked Continue reading... |
The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For AntibioticHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 18) 10X Genomics Inc (NASDAQ: TXG ) Acceleron Pharma Inc ... |
Zafgen and Chondrial Therapeutics Announce Definitive Merger AgreementZafgen, Inc. (ZFGN) and Chondrial Therapeutics, Inc., today announced they have entered into a definitive merger agreement under which Chondrial will become a wholly-owned subsidiary of Zafgen and the stockholders of Chondrial Therapeutics will become the majority owners of Zafgen’s outstanding common stock upon the close of the merger. The proposed merger will result in a combined publicly traded, clinical-stage biopharmaceutical company operating under a new name, Larimar Therapeutics, Inc. |
Is Zafgen Inc (ZFGN) A Good Stock To Buy?Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 20 S&P 500 […] |
Zafgen (NASDAQ:ZFGN) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPSZafgen (NASDAQ:ZFGN) announced its earnings results on Wednesday. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.03, Fidelity Earnings reports. NASDAQ ZFGN traded up $0.02 during mid-day trading on Thursday, reaching $0.76. 457,450 shares of the company’s stock traded hands, compared to its average volume of 359,394. […] |
Zafgen Reports Third Quarter 2019 Financial ResultsEvaluation of strategic alternatives ongoing BOSTON, Nov. 06, 2019 -- Zafgen, Inc. (Nasdaq:ZFGN) today reported its third quarter 2019 financial results. In September. |
The Daily Biotech Pulse: European Nod For Roche, Takeda Recall, Neon Exults On Journal PublicationHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 5) Bioanalytical Systems, Inc. (NASDAQ: BASI ) NextCure Inc (NASDAQ: NXTC ) Pfenex Inc (NYSE: PFNX ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) ResMed Inc. (NYSE: RMD ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 5) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) BioNano Genomics Inc (NASDAQ: BNGO ) Endologix, Inc. (NASDAQ: ELGX ) Mallinckrodt PLC (NYSE: MNK ) ( retreated amid reports of restructuring ahead of Cleveland opioid litigation) Merit Medical Systems, Inc. (NASDAQ: MMSI ) VBI Vaccines Inc (NASDAQ: VBIV ) Zafgen Inc (NASDAQ: ZFGN ) ( announced decision to explore strate... |
Zafgen To Explore Strategic Options, With No Near-Term Resolution For Diabetes DrugClinical-stage biopharma companies often face the risk of running out of cash reserves to fund their operations until they can push their investigational assets out of the clinics and into the commercialization stage. Earlier this week, Abeona Therapeutics Inc (NASDAQ: ABEO ) opted to explore strategic options, and another biotech has now made a similar announcement. What Happened Zafgen Inc (NASDAQ: ZFGN ), a micro-cap biopharma, announced Thursday that it plans to explore strategic options to maximize shareholder value. The strategic alternatives being evaluated include an acquisition, merger, business combination, in-licensing or other strategic transaction involving the company and its … Full story available on Benzinga.com |